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In order to develop a xenograft model to determine the efﬁcacy
of new therapies against primary human precursor-B acute
lymphoblastic leukemia (ALL) stem cells (LSCs), we used the
highly immunodeﬁcient non-obese diabetic (NOD).Cg-Prkdc
scid
IL2rg
tmlWjl/SzJ (NOD-severe combined immune deﬁcient
(scid) IL2rg
 / ) mouse strain. Intravenous transplantation of
2 of 2 ALL cell lines and 9 of 14 primary ALL cases generated
leukemia-like proliferations in recipient mice by 1–7 months
after transplant. Leukemias were retransplantable, and the
immunophenotypes, gene rearrangements and expression
proﬁles were identical or similar to those of the original
primary samples. NOD-scid mice transplanted with the same
primary samples developed similar leukemias with only
a slightly longer latency than did NOD-scid-IL2Rg
 /  mice.
In this highly sensitive NOD-scid-IL2Rg
 / -based assay, 1–100
unsorted primary human ALL cells from ﬁve of ﬁve tested
patients, four of whom eventually experienced leukemia
relapse, generated leukemias in recipient mice. This very high
frequency of LSCs suggests that a hierarchical LSC model is
not valuable for poor-outcome ALL.
Leukemia (2010) 24, 1859–1866; doi:10.1038/leu.2010.184;
published online 26 August 2010
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Introduction
Precursor-B acute lymphoblastic leukemia (ALL) is the most
common form of cancer in children. Although B80% of
children can be cured with current chemotherapy regimens,
cases with high relapse risk can be deﬁned at diagnosis,
1
and relapsed ALL remains a leading cause of cancer deaths
in childhood.
2 Moreover, adult ALL has a much poorer
outcome.
3 It is anticipated that new technologies such as
next-generation sequencing of cancers
4 will identify many new
potential target molecules in ALL, and there will be an
increasing need for predictive preclinical models of human
ALL, to separate ‘driver’ from ‘passenger’ mutations and to
investigate the biology of candidate target molecules.
5 In
addition, preclinical models can speed the evaluation of
rationally targeted agents and their optimal incorporation
into combination chemotherapies.
6 Finally, the cancer stem
cell theory
7–9 predicts that efﬁcacy against LSCs is required
for cure, emphasizing the need for preclinical models that
measure LSCs.
Human leukemia xenografts in immunodeﬁcient mice
have been used quite extensively in drug development.
10 In
B60–70% of primary ALL samples,
11–13 human leukemia-like
proliferations develop in non-obese diabetic (NOD).Cg-
Prkdc
scid (NOD-severe combined immune deﬁcient (scid)) mice
following intravenous injection, as in acute myeloid leukemia
(AML).
8,14–17 These human ALL cells generate clinical signs and
ﬁndings in the NOD-scid mice that closely replicate human
ALL. In addition to providing an operational deﬁnition for LSCs,
the NOD-scid model has predicted patients’ clinical responses
to treatment with established
11 and novel anti-leukemia
agents,
18 alone and in combination.
19 Herein, we describe the
biology after transplant of unpuriﬁed primary human leukemia
cells from several cases of childhood precursor-B ALL into
the highly sensitive NOD.Cg-Prkdc
scidIL2rg
tmlWjl/SzJ (NOD-scid
IL2rg
 / ) mouse strain.
20–22 As our long-term goals were to
develop new understanding and treatment of cases that cannot
currently be cured, we obtained most of these samples from
ALL cases at relapse and/or with high-risk features and/or poor
eventual outcomes.
Materials and methods
Precursor-B ALL cell lines and primary patient samples
The REH and KOPN8 cell lines, derived initially from children
with precursor-B ALL, were obtained from the American
Tissue Culture Collection (Manassas, VA, USA) and the
Deutsche Sammlung von Mikroorganismen und Zelkuturen
GmbH (Braunschweig, Germany), respectively, and were
cultured in RPMI 1640 medium containing 2mML -glutamine,
50U/ml penicillin, 50mg/ml streptomycin (all from Invitrogen,
Carlsbad, CA, USA) and 10–20% fetal bovine serum (Gemini
Bio-products, Calabasas, CA, USA).
Fourteen primary ALL blast samples from children with
precursor-B ALL were obtained from the National Cancer
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leukemia patient cell banks (Supplementary Table 1), under
Institutional Review Board-approved research protocols.
All cryopreserved patient samples contained X94%
CD19
þCD22
þ blast cells. Cells were thawed and resuspended
in PBS before injection into mice. For ﬁve cases, cell dose
titration and transplantation experiments were performed and
LSC frequency was calculated (Table 1). Quintuplicate cell
counts were performed for cells at the highest serial dilutions;
no carrier cells were used. In addition to the actual titered
transplants, two actual (Supplementary Table 5) and one
statistical (Supplementary Table 6) simulation experiments were
performed.
Human ALL-immunodeﬁcient mouse chimera models
The use of mice in this study was approved by the Institutional
Animal Care and Use Committees of Johns Hopkins University
and the University of Maryland. NOD-scid IL2rg
 /  and NOD-
scid mice, obtained initially from the Jackson Laboratory
(Bar Harbor, ME, USA), were bred and housed in the animal
facilities of the Sidney Kimmel Comprehensive Cancer Center at
Johns Hopkins or the University of Maryland School of
Medicine. Mice were handled under sterile conditions in a
laminar ﬂow hood. Sublethally irradiated (250cGy) 6–8-week-
old NOD-scid IL2rg
 /  and NOD-scid mice were injected
intravenously (lateral tail vein) with human ALL cells. Mice were
monitored daily and euthanized if severely ill. For serial
transplantation studies, spleens of euthanized mice were
harvested and dissociated into single-cell suspensions. In all
experiments, the percentage of human CD19
þCD22
þ blastic
leukemia cells in these splenocyte preparations (splenocytes)
was 94–99%.
Histology, ﬂow cytometry, immunoglobulin heavy
chain (IgH) gene rearrangements, molecular
karyotypes, statistics and gene expression microarrays
Please see Supplementary Material.
Results
Human ALL cell lines generated clinical signs of human
ALL and fatal, retransplantable, leukemia-like
proliferations in NOD-scid-IL2Rg
 /  mice
Two childhood precursor-B ALL cell lines were intravenously
transplanted into groups of sublethally irradiated young
adult NOD-scid IL2rg
 /  mice. At approximately 1 month after
transplant of 10
6 cells per mouse of either the REH or KOPN8
ALL cell lines, all recipient mice died suddenly or had severe
clinical signs suggestive of leukemia (Figure 1a), including
pallor, bleeding, weight and hair loss, hunched posture, and rear
limb paralysis. All mice had massive spleens (Figures 1b and c)
and hyperplastic bone marrows at necropsy. Blood, spleens and
marrows were essentially replaced with cells with morpho-
logy (Figure 1d) and human-leukocyte differentiation antigen
immunophenotype matching those of the transplanted
human ALL cell lines (Supplementary Figure 1). Splenocytes
(X94% human blasts) of transplanted mice were successfully
secondarily transplanted into naive NOD-scid IL2rg
 /  mice.
No signiﬁcant differences were observed in times-to-(fatal
clinical) leukemias after secondary, as compared with primary,
transplants (Supplementary Table 2 and Supplementary Figure 5).
Characteristics of the 14 primary human ALL cases
tested
We selected only cases with at least 10 vials of cryopreserved cells
in the bank, so that it would be possible to perform additional
experiments using aliquots of the identical specimen. Eight
ALL samples (ALL cases 1–3, 8, 9 and 12–14) were from multiply
relapsed, chemotherapy-refractory patients, all of whom died of
ALL. ALL case 1 harbored the BCR-ABL translocation, a powerful
poor prognostic factor. ALL cases 12 and 13 harbored the ETV6-
RUNX1 and MYC-IGH translocations, respectively. Six samples
(ALL cases 4–7, 10 and 11) were from patients at initial diagnosis,
before chemotherapy. ALL cases 4 and 7 relapsed after 0.9 and
3.5-year continuous complete remissions (CCRs), respectively, and
died of ALL. ALL cases 5, 6, 10 and 11 remain in CCR at 45, 45,
43.5 and 44 years, respectively (Supplementary Table 1).
Table 1 High LSC frequencies in each of ﬁve primary childhood precursor-B ALL cases and two childhood precursor-B ALL cell lines
ALL primary case
or cell line
Frequency of leukemia (post-transplant days to leukemia)
a LSC
frequency (%)
10
6 cells 10
5 cells 10
4 cells 10
3 cells 10
2 cells 10 cells 1 cell 0 cells
ALL case no. 1 3/3 (35) 3/3 (42) 3/3 (50) 3/3 (58) 5/5 (66) 3/10 (76) 0/10 (207) 0/3 (207)
b 1.95*
ALL case no. 2 3/3 (49) 3/3 (55) 3/3 (61) 3/3 (67) 5/5 (79) 0/10 (194) 0/10 (194) 0/3 (194)
b 1.30**
ALL case no. 3 3/3 (72) 3/3 (88) 3/3 (95) 3/3 (115) 5/5 (143) 10/10 (174) 2/8 (208) 0/3 (230)
b 23.90*
ALL case no. 4 3/3 (65) 3/3 (80) 3/3 (113) 3/3 (135) 4/5 (161) 0/10 (243) 0/10 (243) 0/3 (243)
b 1.03*
ALL case no. 5 3/3 (90) 3/3 (95) 3/3 (116) 3/3 (120) 5/5 (140) 0/10 (243) 0/10 (243) 0/3 (243)
b 1.30**
REH 3/3 (28) 3/3 (32) 3/3 (38) 3/3 (45) 2/5 (55) 0/10 (138) 0/10 (138) 0/3 (138)
b 0.74**
KOPN8 3/3 (28) 3/3 (33) 3/3 (40) 3/3 (53) 3/5 (61) 0/10 (145) 0/10 (145) 0/3 (145)
b 0.86**
Abbreviations: ALL, acute lymphoblastic leukemia; LSC, leukemia stem cell.
aValues shown represent numbers of mice with leukemia/all mice transplanted with the dose of ALL cells speciﬁed for that column (mean post-
transplant days to leukemia; for every experimental group, all mice in the group developed clinical signs within 3 days after the ﬁrst mouse).
For each case, the data are in bold for the lowest cell dose resulting in leukemias.
bDay at which the experiment was terminated. Each mouse that had not developed clinical signs of leukemia was killed at the end of the experiment
for that group (i.e. 22–131 days after the day when the last mouse transplanted with cells from that ALL case developed clinical signs of leukemia);
absence of leukemia was conﬁrmed in each of these mice by necropsy showing normal-sized spleen and ﬂow cytometry detecting no human
ALL blasts.
*P-value of trend (P value of the F statistic) o0.001.
**P-value of trend (P value of the F statistic) o0.01.
Titered doses of unpuriﬁed precursor B-ALL primary cells or cell lines were transplanted into NOD-scid IL2rg
 /  mice.
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LeukemiaOut of 14 primary ALL cases tested, 9 generated fatal,
retransplantable human ALL in NOD-scid-IL2Rg
 / 
mice
All mice transplanted with 10
6 ALL cells from each of 9 of the
above 14 (64.3%) primary cases tested (that is, ALL cases 1–7,
12 and 13) died or developed severe clinical signs suggestive of
leukemia and requiring euthanasia (Figure 1a). Clinical signs
and necropsy results in these mice were similar to those
observed in mice transplanted with the REH and KOPN8 ALL
cell lines. Times-to-leukemia in transplanted mice varied from 1
to 7 months after transplant, depending on the primary ALL case
(Figure 1a). Splenocytes from these cases were successfully
secondarily transplanted into naive NOD-scid IL2rg
 / mice
(Supplementary Table 2 and Supplementary Figure 5).
Mice transplanted with 10
6 cells from 5 of the 8 (62.5%)
primary samples obtained from patients at relapse (ALL cases
1–3, 12 and 13) developed leukemias, at 1–3 months post-
transplant. Mice transplanted with 4 of the 6 (67%) primary
samples obtained from patients at initial diagnosis (ALL cases
4–7) developed leukemias more slowly, at 2–7 months post-
transplant, but the difference was not signiﬁcant in this small
sample (P¼0.15). There were no consistent immunophenotypic
differences between the set of ALL cases (1–7, 12 and 13) that
generated leukemias in mice and the set of cases (8–11 and 14)
that did not engraft.
Immunophenotypes of splenocytes from transplanted
immunodeﬁcient mice were similar to those of the
pre-transplant ALL samples
Primary cells from each of the childhood precursor-B ALL cases
strongly expressed human CD45 and the human CD10, CD19
and CD22 B-lymphoid markers (Supplementary Figure 1). ALL
cases 1 and 3–7 expressed human CD20; cases 1, 3, 4, 6, 7 and
13 expressed human CD34. For ALL cases 1–4, 6, 7 and 12, the
human-leukocyte differentiation antigen immunophenotypes
of the cells harvested from the blood, spleens and marrows of
recipient mice closely matched those of the transplanted human
primary patient samples, qualitatively and quantitatively for
every tested monoclonal antibody (Supplementary Figure 1).
Cells from mice transplanted with ALL case 5 had decreased
CD19 intensity, as compared with the primary sample
ALL case#12
ALL case#13
REH
KOPN8 a
ALL case#2
ALL case#3
ALL case#4
ALL case#5
ALL case#6
ALL case#7
0 50 100 150 200 250
ALL case#1
c b
d
Transplanted Control
Figure 1 Nine of fourteen primary childhood precursor-B ALL cases and two of two cell lines generated leukemia-like proliferations in NOD-scid
IL2rg
 /  mice 1–7 months after intravenous transplantation of one million cells (a). Massive splenomegaly was the most prominent gross
pathologic feature in all the mice (b, c), accompanied by replacement of blood, spleen and marrow by human cells with the blast morphology of
the original precursor-B ALL cases and cell lines (d).
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observed in ALL case 5 cells from secondarily transplanted
mice. The immunophenotype of cells from mice transplanted
with ALL case 13 had somewhat increased CD34 intensity, as
compared with the primary sample (Supplementary Figure 1).
None of the tested primary cases or human cells from mice
expressed either the CD13 or the CD33 human myeloid
markers.
The patient-speciﬁc clonal gene rearrangements of the
primary samples were observed in splenocytes from the
immunodeﬁcient mice
In all ﬁve primary cases tested (ALL cases 1–5), immunoglobulin
heavy chain VH to JH, or VH to DH to JH, rearrangements were
identical in primary samples and in the corresponding spleno-
cytes from the recipient mice (Supplementary Figure 2).
Molecular karyotyping of ALL cases 1–5 revealed that the
BCR–ABL translocation in primary cells was obtained directly
from the patient and from splenocytes of the transplanted mice.
In four of ﬁve cases, global gene expression patterns
closely matching those of the primary samples were
observed in splenocytes from immunodeﬁcient mice
We performed cDNA microarray analyses on ALL cases 1–5
before and after transplant into NOD-scid IL2rg
 /  mice. By
unsupervised hierarchical clustering using all probes on the
array, four of the ﬁve tested primary samples clustered nearest to
their counterpart splenocytes from transplanted mice (Supple-
mentary Figure 3). Exceptionally, the global gene expression of
splenocytes from mice transplanted with ALL case 5 differed
somewhat from that of the primary sample (Supplementary
Figure 3). In the data from all ﬁve ALL cases, expression levels of
only a small number of genes (o5%) differed by twofold or
more between primary cells and splenocytes (Supplementary
Figure 4).
Titrations of transplanted cell dose to quantitate LSC
frequencies
All NOD-scid IL2rg
 /  mice transplanted with X1000 REH
or KOPN8 cells developed clinically severe leukemias by p53
days (mean) post-transplant. In all, 60 or 40% of mice
transplanted with 100 REH or KOPN8 cells developed
leukemias by 61 or 55 days, respectively (Table 1). Mice scored
as not developing leukemia were observed for at least 3 weeks
beyond the time that the ﬁnal mouse developed leukemia; at this
time, necropsy revealed normal organ size and appearance, and
ﬂow cytometry detected no human ALL blast cells. Calculated
LSC frequencies were 0.74% for the REH and 0.86% for the
KOPN8 cell line. In both REH and KOPN8 cell lines, the times-
to-leukemia correlated with the number of cells transplanted,
following an inverse log(cell dose)–linear(time) model (Po0.01
for the trend) (Supplementary Figure 5).
Next, we transplanted titered doses of unpuriﬁed primary
childhood precursor-B ALL cells from ﬁve of the primary
cases that had generated leukemias in mice by p100 days
after transplant of 10
6 ALL cells (ALL cases 1–5); this 100-day
criterion was selected because it was anticipated that lower cell
doses would require very long times to generate leukemias. For
each ALL case tested, times-to-leukemia in the transplanted
mice followed an inverse log-linear model (Po0.01) (Table 1
and Supplementary Figure 5). As above, the NOD-scid IL2rg
 / 
mice within each experimental group (that is, transplanted with
the same dose of the same case) developed clinical signs of
leukemia with little variation in time (o3 days). In all ﬁve
of these primary ALL cases, 100% of the NOD-scid IL2rg
 / 
mice transplanted with 10
3–10
6 unpuriﬁed cells developed
leukemias by 135 days (Table 1), and secondary transplants
resulted in leukemias with times-to-leukemia closely similar to
those of the initial transplants (Po0.05) (Supplementary Table 2
and Supplementary Figure 5).
All mice transplanted with X100 unpuriﬁed cells from
primary ALL case 1 developed severe leukemias by p66 days
post-transplant, and 3 of 10 mice transplanted with 10 cells
developed leukemias by 76 days post-transplant. However,
none of the 10 mice transplanted with one cell developed
clinical leukemia by 207 days; at this time point, the experiment
was terminated and ﬂow cytometry detected no leukemia in the
mouse splenocytes. The calculated LSC frequency in ALL case 1
was 1.95% (even higher than that for the REH and KOPN8 cell
lines). Secondary transplant of 10 splenocytes from mice that
had been transplanted with 10 primary cells from ALL case 1
generated leukemias, with time-to-leukemia closely similar to
that observed after the initial transplant of 10 primary cells
(Po0.01) (Supplementary Table 2 and Supplementary Figure 5).
With primary ALL case 2, all mice transplanted with X100
unpuriﬁed cells developed severe leukemias by p79 days post-
transplant. However, none of 10 mice transplanted with 10 cells
or 1 cell developed clinical leukemia by termination of the
experiment at 194 days, and no leukemia cells were detected in
the mouse splenocytes by ﬂow cytometry. Thus, in ALL case 2,
the time-to-leukemia was somewhat longer than in ALL case 1,
and the calculated LSC frequency was also somewhat lower
(1.30%). Secondary transplants of splenocytes from mice that
had been transplanted with 100 primary cells from ALL case 2
generated leukemias, with time-to-leukemia being similar to
that observed after the initial transplant of 100 primary cells
(Po0.01) (Supplementary Table 2 and Supplementary Figure 5).
With primary ALL case 3, all mice transplanted with X10
unpuriﬁed cells developed severe leukemias by p174 days
post-transplant. Two of eight mice transplanted with one
primary ALL cell developed leukemia by 208 days; however,
the remaining six mice in this experimental group transplanted
with one cell did not develop clinical leukemia by termination
of the experiment at 230 days, when no leukemia was detected
in the mouse splenocytes by ﬂow cytometry. Secondary
transplant of splenocytes from mice that had been transplanted
with one primary cell generated leukemias, with time-to-
leukemia being similar to that observed after the initial
transplant of one primary cell (Po0.05) (Supplementary
Table 2 and Supplementary Figure 5). ALL case 3 had the
highest LSC frequency (23.9%) among the ﬁve titered cases, but
the second longest time-to-leukemia, indicating lack of corre-
lation between these two variables. Experimental (using REH
cells) and statistical simulations were performed to model
the likelihood of possible cell dose variations among mice
in the experimental group intended to receive one ALL case 3
cell. The results suggested that it was unlikely that only two
mice in the simulated experimental group received all the
cells intended to be evenly distributed among the 10 mice
transplanted (Po0.05) (Supplementary Tables 5 and 6).
With primary ALL case 4, all mice transplanted with X1000
unpuriﬁed cells and four of ﬁve mice transplanted with 100
cells developed severe leukemia by p161 days. Neither the
remaining one mouse in the experimental group transplanted
with 100 cells nor any of the mice transplanted with 10 cells or
1 cell developed clinical leukemia by termination of the
experiment at 243 days, and no leukemia cells were detected
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transplant of splenocytes from mice that had been transplanted
with 100 cells generated severe leukemias, with similar time-
to-leukemia to that observed after the initial transplant of 100
primary cells (Po0.01) (Supplementary Table 2 and Supple-
mentary Figure 5). ALL case 4 had a calculated LSC frequency
of 1.03%.
With primary ALL case 5, all mice transplanted with X100
cells developed severe leukemias by p140 days. None of
the mice transplanted with 10 cells or 1 cell developed
clinical leukemia by termination of the experiment at 243 days,
and no leukemia cells were detected in the mouse spleens by
ﬂow cytometry. Secondary transplant of splenocytes from mice
that had been transplanted with 100 cells generated leukemias,
with similar time-to-leukemia to that observed after the
initial transplant of 100 primary cells (Po0.01) (Supplementary
Table 2 and Supplementary Figure 5). ALL case 5 had a
calculated LSC frequency of 1.30%.
Transplants in classical NOD-scid mice
To examine whether our observations might be dependent on
the use of the new highly immunodeﬁcient NOD-scid IL2rg
 / 
mouse strain, a somewhat more restricted number of cell doses
was simultaneously titered into classical NOD-scid mice. As
with the NOD-scid IL2rg
 /  mice, time-to-leukemia in the
transplanted NOD-scid mice was dependent on (1) ALL case
and (2) ALL cell dose. The onset of leukemia was delayed by
up to 3 weeks in the NOD-scid model compared with the
NOD-scid IL2rg
 / , but both immunodeﬁcient mouse models
indicated that low numbers of transplanted ALL cells gene-
rated leukemias (Supplementary Table 3 and Supplementary
Figure 6). Several of the transplanted NOD-scid mice had to be
censored because of deaths due to murine thymic lymphomas
that occur spontaneously in this strain.
23
Discussion
In most cases, primary precursor-B ALL cells undergo rapid
apoptosis in vitro. Although addition of cytokines and stromal
feeder cells to cultures can prolong ALL cell survival for hours to
days, few cases proliferate and expand ex vivo.
24–29 In contrast,
many previous studies have shown that primary cells from the
majority of cases of human acute leukemias can overcome
the histocompatibility barrier after intravenous transplant into
immunodeﬁcient mice to engraft, survive, proliferate and
disseminate, especially in the bone marrow and other hemato-
poietic organs. The resulting human leukemia-like cell pro-
liferations in this xenogeneic environment are quite similar to
human clinical leukemias.
24,30–32 Thus, the growth of primary
human leukemia cells in immunodeﬁcient mice offers an
attractive assay for studies of leukemia biology and treatment,
and such xenograft assays in NOD-scid mice provide the current
‘gold-standard’ assay for LSCs.
7,9 It should be noted that most of
these leukemia xenograft studies have been done with human
AML, and many AML cases proliferate in a relatively benign
manner in NOD-scid mice without causing death of the
mice.
8,14,33
Because of absent IL15 signaling, NOD-scid IL2rg
 /  mice
completely lack even the low levels of natural killer cells present
in classical NOD-scid mice. As compared with classical NOD-
scid mice (and principally ascribed to their complete natural
killer cell deﬁciency), NOD-scid IL2rg
 /  mice may allow
higher-level engraftment of normal human hematopoietic stem
cells
20–22 and acute leukemias.
34–36 Therefore, we charac-
terized the generation of human ALL in highly immunodeﬁcient
NOD-scid IL2rg
 /  mice. The choice of recipient mouse strain
can affect measured LSC frequencies,
21,36,37 and Quintana
et al.
38 reported that NOD-scid IL2rg
 /  mice provide a
signiﬁcantly more sensitive assay of human melanoma stem
cell engraftment and growth than classical NOD-scid mice. In
our experiments, ALL cases 1–5 generated leukemias at low
transplanted cell doses in both NOD-scid IL2rg
 /  and classical
NOD-scid mice. Whereas in ALL cases 3–5 the times-to-
leukemia were not substantially different in NOD-scid IL2rg
 / 
versus NOD-scid mice, the slightly longer times-to-leukemia
observed in ALL cases 1 and 2 in NOD-scid mice suggest that
the presence of greater immune function (for example, natural
killer cells) in the NOD-scid mice may slow the growth of
some leukemia cases. In addition, several of the transplanted
NOD-scid mice had to be censored because of deaths due
to endogenous mouse thymic lymphomas known to occur
spontaneously in this strain.
23 Thus, although we found
pragmatic advantages to use of NOD-scid IL2rg
 /  mouse
recipients for modeling the engraftment and growth of primary
human ALL cells, especially for cases with long times-to-
leukemia, our limited comparisons in NOD-scid versus NOD-
scid IL2rg
 /  mouse recipients suggest that use of classical
NOD-scid mice would not have affected our overall scientiﬁc
conclusions discussed below.
As we had observed multiple radiation-related deaths in the
ﬁrst few weeks after transplant in experiments involving
radiation doses X300cGy (data not shown), we chose to
administer a slightly lower dose (250cGy) to recipient mice
before transplant, and we observed few deaths in radiation-
control mice. We have found that small numbers of ALL case 1
cells generated leukemias in mice treated with only
100–200cGy (data not shown); however, we did not system-
atically investigate the reduction in radiation dose. Spiegel et al.
39
found that radiation-induced upregulation of stromal cell-derived
factor-1 (SDF-1) reduced engraftment of ALL blasts in NOD-scid
recipients, and engraftment of precursor B-ALL cases has been
reported in non-irradiated mice.
32,36 Thus, future experiments
using non-irradiated hosts might lead to an increase in the
frequency of ALL cases that generate leukemias upon transplant
in mice and/or the calculated frequency of LSCs. Similarly, our
use of the intravenous route for transplant of ALL cells might have
led to an underestimation of the true LSC frequency because of
inefﬁcient homing of cells to a lymphopoietic niche; thus, intra-
femoral transplantation
40–42 and/or introduction into neonatal
mouse liver
43 might increase the measured LSC frequency by as
much as 10-fold. Nevertheless, such technical modiﬁcations
designed to enhance leukemia engraftment would not alter our
data interpretation that ALL LSCs are frequent.
Both the REH and KOPN8 precursor B-ALL cell lines gene-
rated clinical leukemias at B1 month after intravenous transfer
of 10
6 cells into sublethally irradiated NOD-scid IL2rg
 /  mice.
Preliminary experiments (not shown) demonstrated that human
leukemia cells could be detected by immunostaining and
ﬂuorescence-activated cell sorting (FACS) analysis in mouse
blood as early as 2 weeks post-transplant, considerably before
the onset of clinical signs, as in human clinical ALL. Massive
splenomegaly was the most prominent gross pathological
feature in all the mice, accompanied by replacement of blood,
spleen and marrow by human cells with the blast morphology
and immunophenotype of the original cell lines. Secondary
transplants of splenocytes from transplanted leukemic mice
regenerated the characteristic human leukemias. When we
titered the transplanted cell dose of these two ALL cell lines,
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dose and time-to-leukemia. This model should facilitate future
quantitative comparisons of the effects of gene modiﬁcations or
drug treatments with the transplantation efﬁciency of ALL cell
lines. We were not surprised that low cell doses (p100 cells) of
these cell lines generated leukemias in the mice, as we expected
that the frequency of LSCs might be quite high in established
autonomous cell lines.
44 Based on these observations using cell
lines, we proceeded to characterize primary B-precursor ALL
cells in this same assay.
Of the eight tested cases of childhood precursor-B ALL
obtained at relapse, 5 (62.5%) generated leukemias in NOD-
scid IL2rg
 /  mice after intravenous transplant of 10
6 primary
cells. A similar frequency (67%) of the six cases of childhood
precursor-B ALL obtained at initial diagnosis generated leuke-
mias in NOD-scid IL2rg
 /  mice; cases 5 and 11 had standard
risk features based on patient age and white blood cell count at
diagnosis (and case 11 harbored the good-risk ETV6–RUNX1
translocation) and remain in CCR; cases 6 and 10 had
poor prognostic features, yet remain in CCR; cases 4 and 7
had poor prognostic features and have relapsed and died.
Previous publications
30,32 have reported that similar overall
frequencies (40–80%) of ALL cases generated leukemias in
immunodeﬁcient mice. In AML, it has been shown that poor
prognostic ‘virulence’ features, such as FLT3 mutations,
correlate with the ability to generate leukemias in immuno-
deﬁcient mice
8,14,15 and that, for unknown reasons, some
AML subtypes such as acute progranulocytic leukemia (FAB
(French–American–British) M3) rarely, if ever, engraft.
8 In
ALL, samples from patients at relapse tend to generate
leukemias more rapidly than samples from patients at initial
diagnosis,
12,45 and short length of ﬁrst remission has been
shown to predict for particularly rapid leukemia generation in
NOD-scid mice.
12 Conceivably, failure to generate leukemia
could be due to not only the low ‘virulence’ of the given case
but also factors such as display of recognition factors susceptible
to residual NOD-scid IL2rg
 /  mouse (innate) immunity on
blast cells or the dependence of the LSCs on human micro-
environmental survival or absence of proliferation signals in
the mouse host environment,
46,47 irrespective of the true LSC
frequency. Investigation of factors associated with LSC engraft-
ment and growth in this xenogeneicmodel was not our main
goal and will require testing of large numbers of the diverse
subtypes of ALL cases.
Although as discussed above, additional reﬁnements may be
advantageous, this NOD-scid IL2rg
 /  model provides a robust
and reliable pre-clinical assay to investigate LSC biology and to
determine the efﬁcacy of new agents in those cases that generate
leukemias in this modelFthe majority of cases of precursor-B
ALL.
30,32 In contrast to most cases of AML, all nine of the
childhood precursor-B ALL cases that engrafted generated fatal
leukemias, with human blasts essentially replacing hemato-
poietic organs and disseminating throughout other tissues of
the mice. Times-to-leukemia varied from 1 to 7 months after
transplant, despite the fact that these samples were all fully
evolved leukemia cells from patients with clinical leukemias.
The observation that the NOD-scid IL2rg
 /  mice within an
experimental group developed clinical signs of severe leukemia
with minimal variability within experimental groups makes it
unlikely that additional mutations in the leukemia cells are
required for the development of leukemias in these xenografts,
as the time taken to develop such necessary additional
mutation(s) would be expected to vary among mice. Our cases
of ALL obtained at relapse tended to generate leukemias more
rapidly in mice than did our cases obtained at initial diagnosis
(P¼0.15). Although small numbers limit its statistical signiﬁ-
cance, this trend is consistent with the literature.
12
In all ﬁve of the primary ALL cases tested, titered secondary
transplants of ALL cells generated severe leukemias in NOD-
scid IL2rg
 /  mice, with times-to-leukemia being closely similar
to the corresponding initial transplants (Po0.05). In some
reports, shortened times-to-leukemia were observed after serial
transplant.
31 Perhaps, we would have seen such an evolution to
more rapidly growing leukemias after multiple passages in mice,
as Liem et al.
11 observed that the times-to-leukemia were
closely similar in initial versus secondary transplants of 10 ALL
cases but that times-to-leukemia tended to decrease in tertiary
transplants. On the other hand, most of our high-risk ALL cases
might have evolved extensively already in the patients, such that
further evolution during the course of their growth in mice
produced insigniﬁcant additional proliferation/survival advan-
tages. In any case, results similar to our own have been
previously reported for secondary xeno-transplants of human
AML,
14 ALL,
12,30 colorectal cancer and breast cancer.
9
The same IgH gene rearrangements were present in spleno-
cytes from all ﬁve tested transplanted mice, as compared with
samples obtained directly from the corresponding patients. In
seven of the nine cases tested, comparisons of the initial patient
sample with samples obtained after initial and secondary mouse
transplants revealed that the leukemia cell immunophenotype
was essentially unchanged by in vivo expansion of the leukemia
in the mouse. In ALL cases 5 and 13, expression of CD19 or
CD34 (respectively) was slightly different after transplant. The
changed CD19 expression was stable in secondary transplanted
ALL case 5 cells, suggesting a shift in gene expression possibly
induced by the xenogeneic microenvironment. (Immuno-
phenotype was not examined after secondary transplant of
ALL case 13.) The mechanism of this potential artifact may be
post-transcriptional, as the CD19 mRNA level was not altered
in ALL case 5 (Supplementary Figure 4). Similar small changes
in immunophenotype have been reported in a minority of ALL
cases.
11 Global gene expression proﬁles of ALL cases 1–4 were
conserved between the primary sample and splenocytes
of counterpart transplanted mice, consistent with previous
reports.
14 In ALL case 5, global gene expression was slightly
altered after transplant. For all ﬁve cases tested, the times-
to-leukemia were not signiﬁcantly different between initial
and secondary transplants; perhaps this characteristic is more
important than gene expression, as engraftment and growth
reﬂect complex functionality, as opposed to a speciﬁc marker(s).
Therefore, we have listed, but not further investigated, the most
differentially expressed genes (Supplementary Figure 4 and
Supplementary Table 4).
Previous studies using classical NOD-scid mice have
reported that LSCs were enriched in CD19
þ,
24,48,49
CD34
þCD19
 24,27,28,50 or CD133
þCD19
 51 subpopulations
of childhood precursor-B ALL cells. More recent studies, using
the more highly immunodeﬁcient NOD-scid IL2rg
 /  mouse
strain, found LSCs in each of two (that is, CD34
þCD19
þ
CD38
þ and CD34
þCD19
þCD38
 )
34 or three (that is,
CD34
þCD19
 , CD34
þCD19
þ and CD34
 CD19
þ) puriﬁed
ALL cell subsets.
32 We did not observe large cell subsets deﬁned
by immunological markers in our cases (Supplementary Figure 1),
and chose not to re-study such immunological fractionation
of LSCs. Our results, obtained by transplantation of unpuriﬁed
ALL cells, were not confounded by any potential effects of
monoclonal antibodies on LSC engraftment capacity.
52
Our most important ﬁnding was that the LSC frequency in the
ﬁve tested precursor-B ALL cases was 1–24%, much higher than
has been described in AML.
8,33,35 Although we did not verify the
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consistent times-to-leukemia within experimental groups of
mice and consistent log-linear relationships to cell dose. In
addition, the probability that recipient mice received approxi-
mately the intended dose was conﬁrmed by experimental and
statistical simulation for ALL case 3. Importantly, the times-
to-leukemia and LSC frequencies were reproduced in repeated,
independent initial and secondary transplant experiments.
Moreover, two recent abstracts have described the engraftment
of unsorted precursor-B ALL cases at similar low doses.
41,42
Thus, we have high conﬁdence that the LSC frequency is high in
these ALL cases. These ﬁndings are similar to those obtained via
similar limiting-dose transplantation assays in genetic models in
which B10–200 mouse or human model cancer cells generated
leukemia/lymphomas
53–56 in syngeneic mice, as well as the
previously mentioned results with primary human melanomas.
38
A number of factors suggest that the true frequencies of LSCs
may be perhaps 10–100-fold higher than those estimated in our
study. All the primary samples tested had been obtained from
patients in hospitals and required transport to a research
laboratory, cryopreservation and thawing before injection into
mice. After intravenous injection, LSCs presumably had to home
to a suitable niche.
46 Recent evidence suggests that the LSC
model may be enhanced by experimental manipulations
including omission of radiation,
32,36 and/or intrafemoral or
intrahepatic transfer.
40–43 Consequently, the true LSC frequency
in some ALL samples may approach 100%, especially in ALL
cases 1 and 3. On the other hand, our ﬁnding that 9 of 14
primary human ALL cases generated leukemias in mice is
comparable to the frequencies of leukemia reported with
injections at other sites, and our observed generation of
leukemias after intravenous injection of very low ALL cell doses
suggests that homing was highly efﬁcient in these ALL cases.
The hierarchical cancer stem cell model posits that primary
human cancers are organized similarly to the normal hemato-
poietic system, with only the rare cancer stem cell possessing
extensive self-renewal and differentiation capacities.
37 In con-
trast, in stochastic cancer models, most or all cancer cells can
self-renew and generate cancer heterogeneity.
57 The results of
our studies described above suggest that many, most or even all
precursor-B ALL cells are functional LSCs. Thus, it seems that
precursor-B ALL cells may follow a stochastic model, in which
the cancer cells are biologically homogeneous with respect to
their self-renewal capacity. As we assessed LSC frequencies
mainly in ALL cases obtained either at relapse or at initial
diagnosis from patients with poor prognosis and outcomes (of
the ﬁve cases titered for LSC frequency, only ALL case 5 was
cured), our ﬁndings require conﬁrmation in a larger variety and
number of ALL subtypes before generalization to the many
clinically and molecularly deﬁned subtypes of precursor-B ALL.
Nevertheless, the very high frequency of LSCs observed herein
suggests that a hierarchical LSC model is not valuable for
poor-outcome ALL.
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